Perhaps good news for the localities suffering from Dengue fever. However, taming the mosquito is more important.
Sanofi partners with vaccine group on Dengue fever
LONDON (Reuters) – France’s Sanofi-Aventis is partnering with an international vaccine group to speed the adoption of its experimental dengue fever vaccine, which is currently in late-stage development.
The mosquito-borne disease is a threat to nearly half of the world’s population. Of the estimated 220 million people infected each year, two million — mostly children in Latin America and Asia — develop a severe form called dengue hemorrhagic fever.
There is currently no cure or vaccine for dengue fever but Sanofi has the world’s most clinically advanced vaccine candidate, which entered Phase III clinical testing in Australia in November.